Ultimovacs AS is developing a telomerase-based cancer vaccine that could treat a broader range of cancer patients than the most advanced telomerase vaccine in the clinic by delivering multiple telomerase epitopes rather than a single one.

Human telomerase reverse transcriptase (hTERT) is an attractive cancer target because it is absent from most normal cells but is expressed and active in as many as 90% of tumors, where it helps stabilize the cancer cell genome and drive long-term cell growth.